It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Browsing: biogen idec
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.